Your browser doesn't support javascript.
loading
Multi-target therapy in a lupus patient with diffuse alveolar hemorrhage.
Li, Xue; Chen, Yuxin; Zhang, Jianyu; Li, Ting; Chen, Jian; Lu, Yu; Yang, Liu.
Afiliación
  • Li X; Department of Rheumatology and Immunology, The Third Affiliated Hospital of 117980Guangzhou Medical University, Guangzhou, China.
  • Chen Y; Department of Rheumatology and Immunology, The Third Affiliated Hospital of 117980Guangzhou Medical University, Guangzhou, China.
  • Zhang J; Department of Rheumatology and Immunology, The Third Affiliated Hospital of 117980Guangzhou Medical University, Guangzhou, China.
  • Li T; Department of Rheumatology and Immunology, The Third Affiliated Hospital of 117980Guangzhou Medical University, Guangzhou, China.
  • Chen J; Department of Rheumatology and Immunology, The Third Affiliated Hospital of 117980Guangzhou Medical University, Guangzhou, China.
  • Lu Y; Department of Rheumatology and Immunology, The Third Affiliated Hospital of 117980Guangzhou Medical University, Guangzhou, China.
  • Yang L; Department of Rheumatology and Immunology, The Third Affiliated Hospital of 117980Guangzhou Medical University, Guangzhou, China.
Lupus ; 32(1): 142-148, 2023 Jan.
Article en En | MEDLINE | ID: mdl-36384337
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease based on the pathology of small-vessel inflammation, which can affect multiple organs. Diffuse alveolar hemorrhage (DAH) is a rare and severe complication of SLE with high mortality, most commonly seen in young women. It often appears along with clinical manifestations of sudden dyspnea, hemoptysis, and rapid onset of hypoxemia, which develops into respiratory failure and even multiple organs damage. CASE REPORT: The case of a 28-year-old female who was diagnosed with SLE complicated with DAH is presented here. The patient, who experienced recurring DAH, responded poorly to the common therapy of high-dose glucocorticoid plus cyclophosphamide and plasma exchange. After the treatment was adjusted to a multi-target regimen of glucocorticoid, tacrolimus, mycophenolate mofetil, and belimumab, the symptoms began to improve. CONCLUSION: The multi-target regimen may be a new treatment strategy of SLE complicated with DAH.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Pulmonares / Lupus Eritematoso Sistémico Límite: Adult / Female / Humans Idioma: En Revista: Lupus Asunto de la revista: REUMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Pulmonares / Lupus Eritematoso Sistémico Límite: Adult / Female / Humans Idioma: En Revista: Lupus Asunto de la revista: REUMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China